- Market Capitalization, $K 2,422,734
- Shares Outstanding, K 69,900
- Annual Sales, $ 64,890 K
- Annual Income, $ -55,360 K
- 60-Month Beta 1.80
- Price/Sales 39.92
- Price/Cash Flow N/A
- Price/Book 7.67
|Period||Period Low||Period High||Performance|
| || |
-5.12 (-12.75%)since 11/05/21
| || |
+19.11 (+120.04%)since 09/03/21
| || |
-22.44 (-39.05%)since 12/04/20
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s...
ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and...
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and...
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021...
ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|3rd Resistance Point||38.32|
|2nd Resistance Point||36.88|
|1st Resistance Point||35.95|
|1st Support Level||33.58|
|2nd Support Level||32.14|
|3rd Support Level||31.21|